A purple and pink letter v on a white background.
August 15, 2017

Anti-Aging 101: What Are The 3 Ds?

These treatments are essential techniques for addressing the 3 Ds of aging—degeneration, deflation, and descent. Understanding how these 3 Ds work and how to treat them is vital for the success of any medical aesthetics practice. 

What is Degeneration?

Over time, skin begins to lose its tone and texture. This is caused by lowering levels of collagen and elastin—the building blocks of firm, strong skin. According to some experts, the process of collagen and elastin loss starts around the age of 20— after that, a person produces about one percent less collagen in the skin each year. Without new collagen and elastin to revive the skin, dead cells tend to build up—causing a dull, tired look—and the skin becomes more weathered, fragile, and sensitive to external factors.

Skin damage can come about through extrinsic factors as well, especially ongoing exposure to pollution and UV radiation. It can also be exacerbated by changing hormone levels, variations in diet and hydration, and a history of illness or injury. Genetics can play a role in skin health. These combined factors result in a consistent increase in noticeable signs of damage, like age spots, hyperpigmentation, and static wrinkles.

Some wrinkling is normal for people in any age—these are dynamic wrinkles, fine lines that occur with facial muscle movements, like smile and brow lines. But dynamic wrinkles can become troublesome static wrinkles if the skin can no longer bounce back and firm up. 

These skin concerns can be temporarily treated using injectables that diminish the look of fine lines; neurotoxins can slow down the process by which dynamic wrinkles become static. These conditions can be further treated with skin resurfacing and photorejuvenation procedures using energy- and light-based treatment technology. Combination treatments using energy-based devices, dermal fillers, and even platelet-rich plasma, are also highly effective.

What is Deflation?

Deflation refers to volume loss in the face, usually in the form of subcutaneous fat deposits losing their support and appearing sunken. Our faces are made up of bone, muscle, and pockets of fatty tissue beneath the skin. When we’re young, all these components are at their optimal level of collagen and elastin synthesis. But over time, from bones to fat to skin, the production of these and other proteins starts to trail off, leaving them more brittle, less firm, and more prone to remodeling.

The result is these processes means that the physical shape of our face will continue to change throughout life. Some telltale signs of bony facial aging are visible in the bones under the eye socket and along the cheeks, creating a hollow appearance. At the same time, soft tissue and muscle in the face lose their capacity to support the pockets of subcutaneous fat that help to define facial shape. These concerns can often be treated through energy-based skin tightening treatments that help revitalize collagen production for naturally firmer-looking effects, used in combination with dermal fillers to recreate the appearance of plumped-up skin and tissue. 

What is Descent?

Facial descent is best recognized as sagging skin. Lax tissue and loose skin are most noticeable in the appearance of sunken or hollow cheeks, and hanging skin in the form of jowls under the neck, creating a drooping appearance under the eyes and along the jawline. As a result of tissue degeneration and collagen and elastin loss, skin sags and forms lines and wrinkles, collecting lower down on the face.

Patients can achieve a firmer, tighter, and more youthful appearance with energy-based skin tightening and wrinkle-reducing treatments; these treatments contribute to renewed collagen and elastin production, reducing loose skin and improving overall facial skin descent. Dermal fillers can also be used to restore volume in drooping areas, especially in combination with skin tightening. On the surgical side, descent is often treated with facelifts.

July 28, 2026
TORONTO, July 28, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced it has entered into an exclusive distribution agreement with HIRONIC Co. Ltd. (“HIRONIC”), a KOSDAQ listed South Korean company specializing in medical aesthetic devices, pursuant to which the Company acquires the exclusive right to distribute HIRONIC’s Doublo 2.0 device in the United States and Canada. The “New Doublo 2.0” is a synergistic, multi-energy-based medical device platform for the face and body, equipped with two separate handpieces that enables clinics to offer customer Cold Plasma and RF microneedling treatments. The device has received 510(k) certification from the U.S. Food and Drug Administration, and the Company intends to make it available to customers in the United States during 2H 2026. Venus Concept will support future regulatory approval efforts in Canada for the device and any additional handpiece technologies for both regions. “HIRONIC is a global leader in developing innovative medical aesthetic technologies and we are excited for the new partnership, starting with the Doublo x Venus Signature Edition,” said Rajiv De Silva, Chief Executive Officer of Venus Concept. “With this device, we look forward to offering our customers an innovative, exclusive Cold Plasma and RF Microneedling platform. By combining these complementary technologies, the platform delivers synergistic effects from the epidermis to the dermis, enabling comprehensive skin rejuvenation by addressing multiple skin concerns and enhancing overall skin revitalization. The Doublo also complements our existing portfolio by enhancing the range of treatment modalities for a customizable treatment plan to address each patient’s skin needs. We aim to expand our partnership in the future to bring to our customers additional new and novel technologies from HIRONIC, once regulatory approvals have been obtained.” About Venus Concept Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 9 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus NOVA, Venus Versa, Venus Versa PRO, Venus Bliss, Venus Bliss MAX, Venus Viva, Venus Viva MD, Venus Legacy, Venus Velocity, Venus Epileve and AI.ME. Venus Concept's hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept is backed by Madryn Asset Management, a leading healthcare investment firm that provides capital to innovative growth-stage healthcare companies offering unique and transformative products and technologies. Investor Relations Contact: Damian Yeung, CPA investorrelations@venus.ai View Full Article
May 22, 2026
Skin Cancer Awareness Month highlights prevention and early detection. Learn how dermatologists support care with advanced tools and treatments.
May 22, 2026
Skin cancer radiotherapy improves treatment precision and patient outcomes. Learn how dermatology clinics use it in modern care plans.